Stock Ranking
Healthcare Stock Ranking · November 2026
Published 01 Nov 2026
•
Updated 01 Nov 2026
This sector ranking is based on quantitative metrics grouped into four factors:
Value : measures how expensive a stock is relative to the company’s fundamentalsGrowth : measures how quickly the business is expandingQuality : assesses business durability, with a focus on debt levels, margins, and return on invested capitalMomentum : analyzes the current direction and strength of the stock price trendCompanies with strong fundamentals have historically delivered superior long-term performance. However, quantitative metrics alone are not sufficient to evaluate a business. Understanding how a company operates, along with its catalysts and risks, provides a more complete picture.
Quantitative rankings should be used as a starting point for research rather than as standalone investment decisions.
The ranking includes companies across different market capitalizations. Smaller-cap stocks may offer stronger growth opportunities but generally carry higher volatility and business risk.
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
HCA Healthcare Inc
+99%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 50%
Sector Ranking
Catalysts
Sun Belt growth, outpatient
expansion
Risks
High leverage, labor and
reimbursement
Sector: Healthcare
ClarityVesting.com
HCA Healthcare operates one of the largest hospital networks in the U.S., combining steady demand for medical care with strong margins, solid revenue growth, and powerful cash generation. Its scale and dense local networks make it a major force in hospital services.
Stock analysis HCA Healthcare Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
BeiGene Ltd
+3%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 60%
Sector Ranking
Catalysts
BRUKINSA share gains, pipeline
approvals
Risks
BRUKINSA concentration, BTK
competition
Sector: Healthcare
ClarityVesting.com
BeiGene has become a large commercial oncology company built around BRUKINSA, with fast revenue growth, improving margins, and positive free cash flow. Its move from heavy losses to profitability gives it a much more substantial long-term profile than a typical biotech.
Stock analysis BeiGene Ltd
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Agilent Technologies Inc
+15%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Biopharma QC, CrossLab recurring
revenue
Risks
Lab spending cycles, premium
valuation
Sector: Healthcare
ClarityVesting.com
Agilent supplies essential lab instruments, consumables, software, and services used across drug development, diagnostics, and testing. High margins, recurring service revenue, and durable positions in regulated workflows help define its appeal.
Stock analysis Agilent Technologies Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Exelixis Inc
+217%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 80%
Sector Ranking
Catalysts
Cabozantinib expansion, pipeline
progress
Risks
Cabozantinib reliance, trial
failures
Sector: Healthcare
ClarityVesting.com
Exelixis is a profitable oncology biotech built around CABOMETYX, with strong cash flow, high margins, and low debt. Its unusual combination of commercial scale and biotech growth potential stands out as it works to broaden its cancer pipeline.
Stock analysis Exelixis Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Pro Medicus Limited
+211%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 40%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
U.S. contract wins, cloud imaging
demand
Risks
Rich valuation, contract timing,
U.S. focus
Sector: Healthcare
ClarityVesting.com
Pro Medicus supplies high-performance medical imaging software used by major health systems. With rapid growth, exceptional margins, strong cash generation, and a debt-light balance sheet, it stands out, though the key debate remains valuation.
Stock analysis Pro Medicus Limited
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Veeva Systems Inc
-1%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Vault growth, Data Cloud expansion
Risks
Premium valuation, big-client
spending
Sector: Healthcare
ClarityVesting.com
Veeva Systems provides cloud software for life sciences, covering commercial, clinical, regulatory, quality, and data workflows. Strong recurring revenue, rising cash flow, high margins, and a near-debt-free balance sheet support an especially compelling long-term business profile.
Stock analysis Veeva Systems Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
United Therapeutics Corporation
+212%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 60%
Sector Ranking
Catalysts
Tyvaso DPI growth, transplant
pipeline
Risks
Tyvaso concentration, patent
pressure
Sector: Healthcare
ClarityVesting.com
United Therapeutics is a rare-disease biotech built around a highly profitable pulmonary hypertension franchise. Strong cash flow, minimal leverage, and growing transplant-related ambitions add to its long-term interest.
Stock analysis United Therapeutics Corporation
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Halozyme Therapeutics Inc
+232%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 90%
Sector Ranking
Catalysts
New ENHANZE launches, Royalty
growth, FCF rise
Risks
Partner concentration, High
leverage metrics
Sector: Healthcare
ClarityVesting.com
Halozyme Therapeutics generates royalties and licensing income from its ENHANZE drug-delivery platform, a model that has produced unusual profitability and cash flow for biotech. Its appeal rests on scalable, partner-driven growth backed by commercialized products.
Stock analysis Halozyme Therapeutics Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Encompass Health Corp
+192%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Bed expansion, aging population,
FCF growth
Risks
Medicare rates, staffing costs,
leverage
Sector: Healthcare
ClarityVesting.com
Encompass Health is a specialized rehabilitation hospital operator with national scale, steady revenue growth, rising cash generation, and margins well above much of healthcare. That focused role in post-acute care gives it a distinctive position.
Stock analysis Encompass Health Corp
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
Hinge Health Inc
+204%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 90%
Sector Ranking
Catalysts
Employer wins, payer expansion, FCF
scale
Risks
Competition, margin volatility,
long sales
Sector: Healthcare
ClarityVesting.com
Hinge Health delivers digital musculoskeletal care for employers and health plans, combining software with clinical support. Rapid revenue growth, rising free cash flow, and a very low-debt balance sheet underscore the company’s progress.
Stock analysis Hinge Health Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
ResMed Inc
-8%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Bottom 50%
Sector Ranking
Catalysts
Sleep apnea demand, software
expansion
Risks
Reimbursement pressure, GLP-1
debate
Sector: Healthcare
ClarityVesting.com
ResMed develops sleep apnea and respiratory care devices, masks, and healthcare software. Recurring replacement sales, strong margins, rising cash flow, and low debt give the company a notably attractive long-term business profile.
Stock analysis ResMed Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
BillionToOne Inc
+4%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 80%
Sector Ranking
Catalysts
Oncology rollout, prenatal test
expansion
Risks
Prenatal concentration, premium
valuation
Sector: Healthcare
ClarityVesting.com
BillionToOne develops blood-based diagnostic tests, with prenatal screening serving as its current engine and oncology as its next frontier. Revenue growth and improving profitability have been striking, making it an increasingly important name in modern molecular testing.
Stock analysis BillionToOne Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Cardinal Health Inc
+467%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 80%
Sector Ranking
Catalysts
Specialty expansion, FCF strength
Risks
Thin margins, peer pricing pressure
Sector: Healthcare
ClarityVesting.com
Cardinal Health is a healthcare distribution giant that moves medicines and medical supplies at massive scale. Earnings and cash flow have improved sharply, while specialty services provide a stronger growth angle and add to the company’s momentum.
Stock analysis Cardinal Health Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
National HealthCare Corporation
+234%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Margin recovery, occupancy,
homecare mix
Risks
Medicare rates, staffing costs,
regulation
Sector: Healthcare
ClarityVesting.com
National HealthCare Corporation operates skilled nursing, senior living, and homecare services with a notably strong balance sheet, recovering margins, and rising cash generation. Its appeal comes from resilient care demand combined with unusually disciplined finances.
Stock analysis National HealthCare Corporation
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
Ligand Pharmaceuticals Incorporated
+228%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 90%
Sector Ranking
Catalysts
Royalty pipeline, Captisol, new
deals
Risks
Partner dependence, lumpy revenue,
debt
Sector: Healthcare
ClarityVesting.com
Ligand Pharmaceuticals generates royalties, licensing income, and Captisol-related revenue from a broad portfolio of partnered drug assets. Recent growth, strong margins, and improving cash flow highlight the appeal of its royalty-platform model.
Stock analysis Ligand Pharmaceuticals Incorporated
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
Krystal Biotech Inc
+534%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Vyjuvek growth, pipeline expansion
Risks
Single-product reliance, trial
setbacks
Sector: Healthcare
ClarityVesting.com
Krystal Biotech has grown into a profitable gene-therapy company led by Vyjuvek, with fast revenue growth, strong margins, positive cash generation, and very low debt. The central question is whether that rare-disease foothold can develop into a broader platform.
Stock analysis Krystal Biotech Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
UFP Technologies Inc
+356%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Medical outsourcing, cash flow
growth
Risks
Customer concentration, deal
integration
Sector: Healthcare
ClarityVesting.com
UFP Technologies makes specialized medical components, single-use products, and protective packaging. It has combined rapid revenue growth with strong margins and rising cash flow, reinforcing its niche position in healthcare.
Stock analysis UFP Technologies Inc
This article is for informational purposes only and does not constitute financial advice. Some content is AI-generated. See Disclaimer
